Clean Science Q2 FY27 Earnings Call — Analysis (NSE: CLEAN)
Clean Science posted record revenue led by HALS ramp-up and subsidiary turnaround, but raw material inflation compressed margins amid severe China pricing pressure.
Result quality: stable — Results context unavailable. Management sentiment: neutral.
The take
Q2FY27 Consolidated Revenue ₹295 Cr ( +23% YoY ) . New guidance — Q4FY27 hals capacity utilization 55-60% . New story: HALS scale‑up and product‑mix upgrade .
Results
Consolidated revenue grew 23% YoY to ₹295 Cr, EBITDA rose 6% YoY to ₹92 Cr, and PAT reached ₹56 Cr, supported by HALS revenue doubling YoY and subsidiary turning PAT-positive despite gross margin contraction.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹295 Cr | +23% | yoy · Q2FY27 |
| Consolidated Revenue | ₹295 Cr | +12% | sequential · Q2FY27 |
| Consolidated EBITDA | ₹92 Cr | +6% | yoy · Q2FY27 |
| Consolidated PAT | ₹56 Cr | none · Q2FY27 | |
| Standalone Revenue | ₹226 Cr | +10% | yoy · Q2FY27 |
| Standalone Revenue | ₹226 Cr | +11% | sequential · Q2FY27 |
| Standalone EBITDA | ₹82 Cr | none · Q2FY27 · 36% EBITDA margin | |
| Standalone PAT | ₹55 Cr | none · Q2FY27 · 24% PAT margin | |
| H1 FY27 Consolidated Revenue | ₹559 Cr | +17% | yoy · H1FY27 |
| H1 FY27 Consolidated EBITDA | ₹188 Cr | none · H1FY27 | |
| H1 FY27 Consolidated PAT | ₹129 Cr | none · H1FY27 | |
| Subsidiary Investment | ₹900 Cr | point_in_time · Q2FY27 · Sep-26 |
Guidance
Performance Chemical 2 commercial production targeted for Q4 FY27 (Jan-Feb) aiming for 20-25% utilization in year one, alongside HALS capacity reaching 12,500 MT and utilization ramping to 55-60%.
What management committed to
- The new advanced grade of HALS product [from the Geneus Chem collaboration] will commence commercial launch in H2 FY27, with shipping to Europe starting November or December 2026. — H2 FY27
- HALS capacity utilization, currently at 35-40%, will increase by approximately 50% to reach 55-60% in the coming few quarters [Q3/Q4 FY27]. — 55-60%, Q4FY27
- The backward integration of making key precursors for HALS [ethoxylation facility and another intermediate] will improve margins for those particular HALS products by 5-7%. — 5-7%, FY28
- A 1,000 ton line for the advanced HALS adjacency product [e.g., product 2020] will be commissioned and start commercial production by April or May 2027 [Q1-Q2 FY28]. — Q1-Q2 FY28
- Performance Chemical 2 is targeted to achieve 20-25% capacity utilization in its first year of operation [FY28]. — 20-25%, FY28
Key themes
HALS expansion and raw material headwinds
How the narrative shifted
- HALS scale‑up and product‑mix upgrade: Management frames the strong volume growth as a fundamental shift in customer trust, with backward integration of KSMs positioned as the specific lever for the next leg of margin improvement.
- Strategic collaborations unlocking new markets: The Geneus collaboration has moved from a promising pact to a concrete milestone with completed trials and an imminent launch, while the Kemin element has been dropped from the narrative entirely.
- De‑risking of legacy business: The thread has faded into a background assumption, overtaken by HALS momentum.
- Supply chain headwinds and raw material volatility: The specific China-India phenol price spread is introduced as a structural challenge, framing the margin compression as a necessary strategic trade-off to defend global market share.
- Capacity expansion to drive next leg of growth: The PC2 delay is normalized as a final commissioning challenge, and the narrative pivots to a 'capex-light adjacency' strategy for the next growth cliff.
- Margin resilience from HALS operating leverage: The broad narrative of 'improving EBITDA margins' is replaced by a granular value-capture story focused on specific backward integration projects (KSMs).
- India-China raw material spread suppressing price pass-through: New thread emerging to explain the structural reason for margin compression, downplaying concerns about competitiveness by blaming a transient raw material arbitrage.
Operational commentary
- HALS segment doubled revenue YoY, driven by strong volume ramp; subsidiary CFCL reached PAT positive with 12% EBITDA margin in H1 FY27.
- Export contribution increased to 73% of standalone sales compared to 64% in Q1 FY27.
- Crude-linked feedstock costs (phenol, acetone, methanol) rose 50-100% YoY, but company could not pass on costs due to lower Chinese domestic pricing.
- Performance Chemical 2 scheduled for commercial commissioning in Q4 FY27 (Jan-Feb).
- Hydroquinone/Catechol plant operating at 30-35% capacity utilization, predominantly consumed captively with minor sales in Europe and India.
- Barbituric acid commercialization put on hold due to unremunerative economics against Chinese domestic pricing and high domestic Indian RM costs.
Analyst Q&A
Q. Can the company take price hikes to offset phenol/acetone raw material spikes, and what is the required price increase?
Management declined to quantify the price hike needed, noting they cannot increase prices because Chinese competitors hold prices steady with cheaper local phenol ($1,300 vs $1,550 in India), and Clean Science will not risk losing market share.
Q. What is the EBITDA margin trajectory once HALS utilization reaches 60%?
Management passed on providing outlook, stating that macroeconomic uncertainty and volatile crude oil prices make it impossible to determine.
Q. What is the update on barbituric acid commercialization?
Management put the project on hold because imported raw materials and high Indian inputs made production uncompetitive against Chinese market prices.
Research and educational content only. Not investment advice.